First real-world experience with CardioSecur® in the preclinical setting – When time does matter

Kern, Hanna; Stiepak, Jan; Popp, Erik; Spaich, Saskia; Zelniker, Thomas A; Giannitsis, Evangelos; Katus, Hugo A.; Preusch, Michael

doi:10.1016/j.resuscitation.2017.08.024

Cited by 1 publication

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This may improve the detection of arrhythmia's, leading to further tests and improved identification of underlying cardiac disease. Additionally, in the rare but emergency event of collapse during participation, CardioSecur offers fast, portable ECG monitoring for sports physicians during competition [27,37].…”

Section: Discussionmentioning

confidence: 99%

“…It remains unclear if these leads could assist in detection of structural or electrical disease in athletes. The available literature on this device tests its efficacy in adults and, to date, there are no studies directly comparing amplitudes, durations and waveforms in Cardi-oSecur and the gold standard 12-lead ECG in elite adolescent athletes [27,29]. Therefore, in this study, the agreement in parameter accuracy between CardioSecur's 22-lead mobile ECG and the gold standard 12-lead ECG is investigated in this population.…”

Section: Introductionmentioning

confidence: 99%

“…It has been argued that the gold standard 12-lead ECG neglects right-sided and posterior aspects of the heart [25,26]. Additional leads, offered by CardioSecur (V7-V9, VR3-VR9), have been shown to improve detection of posterior myocardial infarcts [27,28]. It remains unclear if these leads could assist in detection of structural or electrical disease in athletes.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Assessment of a Novel, 22-lead Mobile Electrocardiogram in Elite, Adolescent Footballers

Johnson

Duarte

Ryding³

et al. 2021

Int J Sports Med

View full text Add to dashboard Cite

The 12-lead electrocardiogram is a key component of cardiac screening in elite adolescent footballers. Current technology hampers mobile electrocardiogram monitoring that could reduce the time-to-diagnosis in symptomatic athletes. Recently, a 22-lead mobile electrocardiogram monitor, CardioSecur (Personal MedSystems GmbH), has been approved for use in adults. In this study, the differences in parameter accuracy between CardioSecur’s 22-lead electrocardiogram and the gold standard 12-lead electrocardiogram were assessed in elite adolescent footballers (n=31) using Bland-Altman and paired t-tests/Wilcoxon analysis. Agreement between the two devices was clinically acceptable for heart rate (bias=− 0.633 bpm), PR Interval (bias=− 1.73 ms), Bazzett’s corrected QTc interval (bias=2.03 ms), T-wave axis (bias=6.55°), P-wave duration (bias=− 0.941 ms), Q-wave amplitude (bias=0.0195 mV), Q-wave duration (bias=1.98 ms), rhythm (bias=0.0333), ST-segment (bias=− 0.0629), J-point analysis (bias=− 0.01) and extended T wave and QRS duration analysis. Unsatisfactory agreement was observed in QRS axis (bias=− 19.4°), P-wave axis (bias=− 0.670°), QRS amplitude (bias=− 0.660 mV), P-wave amplitude (bias=0.0400 mV) and T-wave amplitude (bias=− 0.0675 mV). CardioSecur’s 22-lead electrocardiogram agrees with the gold standard in rhythm, durations, T-wave determination in all leads assessed, permitting its use in adolescent footballers for immediate pitch- or track-side analysis.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%